Literature DB >> 24824777

Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma.

Jack Hutcheson1, Ryan J Bourgo, Uthra Balaji, Adam Ertel, Agnieszka K Witkiewicz, Erik S Knudsen.   

Abstract

UNLABELLED: Cancers mediated by viral etiology must exhibit deregulated cellular proliferation and evade immune recognition. The role of the retinoblastoma tumor suppressor (RB) pathway, which is lost at relatively high frequency in hepatocellular carcinoma (HCC), has recently been expanded to include the regulation of innate immune responsiveness. In this study we investigated the coordinate impact of RB-loss on cell cycle control and immune function in the liver. We found that RB depletion in hepatoma cells resulted in a compromised immunological response to multiple stimuli and reduced the potential of these cells to recruit myeloid cells. Viral-mediated liver-specific RB deletion in vivo led to the induction of genes associated with proliferation and cell cycle entry as well as the significant attenuation of genes associated with immune function, as evidenced by decreases in cytokine and chemokine expression, leukocyte recruitment, and hepatic inflammation. To determine if these changes in gene expression were instructive in human disease, we compared our liver-specific RB-loss gene signature to existing profiles of HCC and found that this signature was associated with disease progression and confers a worse prognosis.
CONCLUSION: Our data confirm that RB participates in the regulation of innate immunity in liver parenchymal cells both in vitro and in vivo and to our knowledge describes the first gene signature associated with HCC that includes both immunoregulatory and proliferative genes and that can also be attributed to the alteration of a single gene in vitro.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24824777      PMCID: PMC4482134          DOI: 10.1002/hep.27217

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  42 in total

1.  CCL5-28, CCL5-403, and CCR5 genetic polymorphisms and their synergic effect with alcohol and tobacco consumptions increase susceptibility to hepatocellular carcinoma.

Authors:  Hsiu-Ting Tsai; Shun-Fa Yang; Dar-Ren Chen; Szu-Erh Chan
Journal:  Med Oncol       Date:  2012-02-29       Impact factor: 3.064

2.  Rb/E2F1 regulates the innate immune receptor Toll-like receptor 3 in epithelial cells.

Authors:  Manabu Taura; Mary Ann Suico; Kosuke Koyama; Kensei Komatsu; Rui Miyakita; Chizuru Matsumoto; Eriko Kudo; Ryusho Kariya; Hiroki Goto; Shunsuke Kitajima; Chiaki Takahashi; Tsuyoshi Shuto; Mitsuyoshi Nakao; Seiji Okada; Hirofumi Kai
Journal:  Mol Cell Biol       Date:  2012-02-06       Impact factor: 4.272

Review 3.  Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections.

Authors:  Jimmy K Stauffer; Anthony J Scarzello; Qun Jiang; Robert H Wiltrout
Journal:  Hepatology       Date:  2012-09-11       Impact factor: 17.425

4.  Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.

Authors:  Shin Yoshimoto; Tze Mun Loo; Koji Atarashi; Hiroaki Kanda; Seidai Sato; Seiichi Oyadomari; Yoichiro Iwakura; Kenshiro Oshima; Hidetoshi Morita; Masahira Hattori; Masahisa Hattori; Kenya Honda; Yuichi Ishikawa; Eiji Hara; Naoko Ohtani
Journal:  Nature       Date:  2013-06-26       Impact factor: 49.962

5.  Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74.

Authors:  Daniel Heinrichs; Meike Knauel; Christian Offermanns; Marie-Luise Berres; Andreas Nellen; Lin Leng; Petra Schmitz; Richard Bucala; Christian Trautwein; Christian Weber; Jürgen Bernhagen; Hermann E Wasmuth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

Review 6.  Gene signatures in hepatocellular carcinoma (HCC).

Authors:  Ourania M Andrisani; Leo Studach; Philippe Merle
Journal:  Semin Cancer Biol       Date:  2010-09-17       Impact factor: 15.707

7.  Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.

Authors:  Dianne H Dapito; Ali Mencin; Geum-Youn Gwak; Jean-Philippe Pradere; Myoung-Kuk Jang; Ingmar Mederacke; Jorge M Caviglia; Hossein Khiabanian; Adebowale Adeyemi; Ramon Bataller; Jay H Lefkowitch; Maureen Bower; Richard Friedman; R Balfour Sartor; Raul Rabadan; Robert F Schwabe
Journal:  Cancer Cell       Date:  2012-04-17       Impact factor: 31.743

8.  RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.

Authors:  Adam Ertel; Jeffry L Dean; Hallgeir Rui; Chengbao Liu; Agnes K Witkiewicz; Karen E Knudsen; Erik S Knudsen
Journal:  Cell Cycle       Date:  2010-10-27       Impact factor: 4.534

9.  The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma.

Authors:  Jiang Li; Hui Liu; Linfang Li; Hongping Wu; Chunhong Wang; Zi Yan; Ying Wang; Changqing Su; Huajun Jin; Fuping Zhou; Mengchao Wu; Qijun Qian
Journal:  Oncol Rep       Date:  2012-12-28       Impact factor: 3.906

10.  Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.

Authors:  Valerie Chew; Jinmiao Chen; Deming Lee; Evelyn Loh; Joyce Lee; Kiat Hon Lim; Achim Weber; Ksenija Slankamenac; Ronnie T P Poon; Henry Yang; London Lucien P J Ooi; Han Chong Toh; Mathias Heikenwalder; Irene O L Ng; Alessandra Nardin; Jean-Pierre Abastado
Journal:  Gut       Date:  2011-09-19       Impact factor: 23.059

View more
  13 in total

Review 1.  Universes collide: combining immunotherapy with targeted therapy for cancer.

Authors:  Jennifer A Wargo; Zachary A Cooper; Keith T Flaherty
Journal:  Cancer Discov       Date:  2014-11-13       Impact factor: 39.397

Review 2.  How do persistent infections with hepatitis C virus cause liver cancer?

Authors:  Jonathan K Mitchell; Stanley M Lemon; David R McGivern
Journal:  Curr Opin Virol       Date:  2015-09-29       Impact factor: 7.090

Review 3.  Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.

Authors:  Erik S Knudsen; Steven C Pruitt; Pamela A Hershberger; Agnieszka K Witkiewicz; David W Goodrich
Journal:  Trends Cancer       Date:  2019-04-30

Review 4.  The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy.

Authors:  Jack Hutcheson; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.

Authors:  Afshin Dowlati; Ata Abbas; Timothy Chan; Brian Henick; Xuya Wang; Parul Doshi; Pingfu Fu; Jyoti Patel; Fengshen Kuo; Han Chang; David Balli
Journal:  JCO Precis Oncol       Date:  2022-08

Review 6.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

7.  Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.

Authors:  Brian M Olson; Melissa Gamat; Joseph Seliski; Thomas Sawicki; Justin Jeffery; Leigh Ellis; Charles G Drake; Jamey Weichert; Douglas G McNeel
Journal:  Cancer Immunol Res       Date:  2017-10-19       Impact factor: 11.151

8.  Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations.

Authors:  Malte Simon; Sadaf S Mughal; Peter Horak; Sebastian Uhrig; Jonas Buchloh; Bogac Aybey; Albrecht Stenzinger; Hanno Glimm; Stefan Fröhling; Benedikt Brors; Charles D Imbusch
Journal:  J Transl Med       Date:  2021-05-12       Impact factor: 8.440

9.  Proteomic analysis of pRb loss highlights a signature of decreased mitochondrial oxidative phosphorylation.

Authors:  Brandon N Nicolay; Paul S Danielian; Filippos Kottakis; John D Lapek; Ioannis Sanidas; Wayne O Miles; Mantre Dehnad; Katrin Tschöp; Jessica J Gierut; Amity L Manning; Robert Morris; Kevin Haigis; Nabeel Bardeesy; Jacqueline A Lees; Wilhelm Haas; Nicholas J Dyson
Journal:  Genes Dev       Date:  2015-08-27       Impact factor: 11.361

10.  Rb and p53 Liver Functions Are Essential for Xenobiotic Metabolism and Tumor Suppression.

Authors:  Sathidpak Nantasanti; Mathilda J M Toussaint; Sameh A Youssef; Peter C J Tooten; Alain de Bruin
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.